LCM
ALPN

Lynx1 Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Lynx1 Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,253,183
Closed -$89.3M – 21
2024
Q1 		$89.3M Sell
2,253,183
-1,560,743
-41% -$46.1M 23.01% 1
2023
Q4 		$72.7M Buy
3,813,926
+1,409,312
+59% +$19.6M 28.58% 1
2023
Q3 		$27.5M Sell
2,404,614
-265,858
-10% -$3.27M 18.21% 2
2023
Q2 		$27.5M Sell
2,670,472
-465,701
-15% -$4.2M 17.99% 3
2023
Q1 		$24.2M Buy
3,136,173
+10,000
+0.3% +$79.7K 20.18% 1
2022
Q4 		$23M Buy
3,126,173
+69,753
+2% +$446K 19.87% 2
2022
Q3 		$22M Buy
3,056,420
+1,129,551
+59% +$9.31M 19.85% 2
2022
Q2 		$16.4M Buy
1,926,869
+442,176
+30% +$3.81M 13.97% 4
2022
Q1 		$13.3M Buy
1,484,693
+222,766
+18% +$1.93M 12.37% 3
2021
Q4 		$17.5M Buy
+1,261,927
New +$15.6M 15.25% 3

Lynx1 Capital Management's ALPN Position: Q2 2024 in Review

Lynx1 Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,253,183 shares — an estimated $89.3M sold.

Lynx1 Capital Management first reported a position in ALPN in Q4 2021 and held it in 10 quarters. The position peaked at $89.3M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Lynx1 Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 2,253,183 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $89.3M.
  • Lynx1 Capital Management first reported a position in Alpine Immune Sciences Inc in Q4 2021 and held it in 10 quarters.
  • Lynx1 Capital Management's Alpine Immune Sciences Inc position peaked at $89.3M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.